Hemorrhagic risk in patients who undergo deep brain stimulation on chronic antiplatelet or anticoagulation therapy

Background: Deep brain stimulation (DBS) is the main surgical treatment for medically refractory movement disorders. Many patients are older with medical comorbidities necessitating antiplatelet or anticoagulation use. There is limited data on intracranial bleeding or thromboembolic complications surrounding use of chronic antiplatelet or anticoagulation treatment for patients who undergo DBS surgery.